Notice of Appeal
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
NICE has received 1 appeal, that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:
- Pfizer
The appeal hearing due to be held on Friday 14 July 2023 has been cancelled as the appellant withdrew their appeal.
This page was last updated: